**Chapter 7**

*Healthcare Access - Regional Overviews*

PA: Janssen Biotech, Inc.; 2017

[75] Ilumya [Package Insert].

[76] Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. Journal of Inflammation Research.

[77] Blegvad C, Skov L, Zachariae C. Ixekizumab for the treatment of psoriasis: An update on new data since first approval. Expert Review of Clinical Immunology. 2018;**15**(2):111-121. DOI: 10.1080/1744666X.2019.1559730

[78] Cosentyx [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals

IN: Eli Lilly and Company; 2017

[81] Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opinion on Biological Therapy. 2018;**19**(1):45-54. DOI: 10.1080/14712598.2019.1555235

[82] Kraaij G, Balak D, Busard C, Cranenburgh O, Chung Y, Driessen R, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. British Journal of Dermatology. 2019;**180**:31-42.

DOI: 10.1111/bjd.17198

[79] Taltz [Package Insert]. Indianapolis,

[80] Siliq [Package Insert]. Bridgewater, NJ: Valeant. Pharmaceuticals North

&Co., Inc.; 2018

2016;**9**:39-50

Corporation; 2016

America; 2017

[74] Tremfya [Package Insert]. Horsham,

Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a Subsidiary of Merck

**102**
